Audio summary of JACC: CardioOncology's June issue.

This podcast by Dr. Larissa Araújo de Lucena discusses the development of the ONCO‑DOAC BLEED score for predicting major bleeding in patients with cancer‑associated venous thromboembolism (VTE) receiving direct oral anticoagulants. The findings support a more personalized, risk‑based approach to anticoagulation in cardio‑oncology, integrating cancer type, comorbidities, and clinical factors while highlighting the need for broader validation.

This podcast by Dr. Ron Witteles reviews new data on transthyretin amyloid cardiomyopathy (ATTR‑CM), highlighting differences in transthyretin stabilization between acoramidis and tafamidis across wild-type and variant disease. The discussion underscores the clinical importance of TTR stabilization, emerging biomarkers such as serum transthyretin, and the expanding therapeutic landscape in cardiac amyloidosis.

This podcast by Dr. Dan Zlotoff reviews new research on immune checkpoint inhibitor–associated myocarditis, a rare but serious complication of cancer immunotherapy, focusing on emerging inflammatory biomarkers such as interleukin‑6 and immune cell signatures. The study highlights potential pathways for risk stratification and targeted therapies, while underscoring the need for larger trials to develop reliable diagnostic and treatment strategies in cardio‑oncology.

This podcast by Dr. António Araújo highlights new insights from a large international registry study showing that cancer‑associated upper extremity deep vein thrombosis (UEDVT) carries increased risks of recurrent venous thromboembolism and bleeding. The findings emphasize tumor‑specific risk patterns and support more personalized anticoagulation strategies in cardio‑oncology.

This podcast by Dr. Marie Pigeyre explores emerging evidence on clonal hematopoiesis, highlighting its role as a systemic driver of inflammation and its association with increased risk of cardiovascular disease, stroke, and type 2 diabetes. The discussion emphasizes the growing importance of clonal hematopoiesis in cardiometabolic risk, precision prevention, and aging biology, while noting that routine clinical screening is not yet recommended.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.